PD-1 blockade in tumors with mismatch-repair deficiency

Author(s): Le D, Uram J, Wang H, Bartlett BR, Kemberling H, et al.



Somatic mutations have the potential to encode “non-self” immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade.


We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti–programmed death 1 immune checkpoint inhibitor, in 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency. Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with mismatch repair–deficient colorectal cancers, patients with mismatch repair–proficient colorectal cancers, and patients with mismatch repair–deficient cancers that were not colorectal. The coprimary end points were the immune-related objective response rate and the 20-week immune-related progression-free survival rate.

Similar Articles

Survival and prognostic stratification of 670 patients with advanced renal cell carcionma

Author(s): Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al.

Nivolumab versus Everolimus in advanced renal-cell carcinoma

Author(s): Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al.

Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma

Author(s): Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, et al.

DNA mismatch repair genes in renal cell carcinoma

Author(s): Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, et al.

Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors

Author(s): Altavilla G, Fassan M, Busatto G, Orsolan M, Giacomelli L

Mismatch repair gene mutations in renal cell carcinoma

Author(s): Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, et al.

Mismatch repair-deficient cancers are targets for anti-PD-1 therapy

Author(s): Kelderman S, Schumacher TN, Kvistborg P